Key Highlights
- French pharmaceutical group Servier will purchase Day One Biopharmaceuticals (DAWN) at $21.50 per share in a cash transaction valued at roughly $2.5 billion
- The acquisition price delivers a ~68% premium over DAWN’s Thursday closing price and 86% above its 30-day volume-weighted average
- Shares of DAWN climbed ~66% during premarket hours on March 6, 2026, after the deal announcement
- The board of directors at Day One has given unanimous approval and recommends shareholders tender their shares
- Deal completion is anticipated during Q2 2026, pending regulatory approval and shareholder acceptance
French pharmaceutical company Servier has entered into a definitive agreement to purchase Day One Biopharmaceuticals (DAWN) through an all-cash transaction valued at approximately $2.5 billion. Following the March 6 announcement, DAWN shares jumped roughly 66% in Friday’s premarket session.
https://x.com/FenwickWest/status/2029944210065969265?s=20
According to the acquisition terms, Servier has committed to purchasing all outstanding shares at $21.50 each. This represents a substantial 68% premium above Thursday’s closing price and an impressive 86% premium compared to the 30-day volume-weighted average.
Day One Biopharmaceuticals, Inc., DAWN
The transaction includes no financing contingency, eliminating a typical risk factor that often complicates acquisition closings. The parties anticipate finalizing the deal during Q2 2026, subject to receiving U.S. antitrust approval and majority shareholder acceptance through the tender offer.
Day One’s board of directors conducted a thorough evaluation and unanimously determined to advise shareholders to tender their holdings. The agreement includes customary no-shop provisions along with an $87.7 million termination fee payable under specific circumstances if the transaction fails to close.
Market participants weren’t entirely surprised by the announcement. DAWN shares had already experienced upward movement on Wednesday amid circulating acquisition rumors, with Jazz Pharmaceuticals (JAZZ) and Ipsen (IPSEY) mentioned as potential buyers at that time.
Strategic Assets Driving the Acquisition
The centerpiece of Servier’s acquisition is tovorafenib, Day One’s primary drug candidate designed to treat low-grade glioma — a form of brain cancer. This therapy holds significant promise within pediatric oncology, the therapeutic area where Day One has concentrated its development efforts.
For Servier, this acquisition strengthens its position in rare oncology treatments. The French pharmaceutical company, which generated €6.9 billion in revenue during fiscal 2024/25, currently reinvests approximately 20% of its branded product sales into research and development. Incorporating Day One’s therapeutic portfolio aligns with Servier’s strategic objective to expand its capabilities in precision cancer treatments.
Transaction Framework
The buyout will proceed through an all-cash tender offer mechanism, followed by a backend merger upon satisfying all closing conditions. Servier’s ability to proceed without requiring additional financing arrangements signals strong deal certainty.
The $87.7 million termination fee offers Day One shareholders some protection if the transaction encounters unexpected obstacles.
Before the acquisition announcement, Wall Street analysts had established a $17.00 price target on DAWN shares with a Buy rating — significantly lower than the agreed $21.50 purchase price.
Day One’s market capitalization immediately before the deal announcement was around $1.35 billion. The $2.5 billion enterprise value demonstrates the considerable premium Servier is willing to pay for access to the clinical pipeline.
Day One operates from its headquarters in Brisbane, California. Upon successful completion, the acquisition will transfer complete ownership to Servier, a privately-held French pharmaceutical group with distribution across more than 130 countries worldwide.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
